FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

New discoveries reveal how acute myeloid leukemia walks line between growth and cell death
(University of Chicago) Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2021 Category: International Medicine & Public Health Source Type: news

Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML
(American Association for Cancer Research) The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 16, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for July 14, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a promising combination therapy for acute myeloid leukemia, understanding mechanisms driving resistance to PARP inhibitors, a therapeutic neoantigen vaccine to treat lung cancer, a novel treatment for triple-negative breast cancer and a new understanding of how telomeres may drive inflammatory bowel disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Inhibitory effects of Tomivosertib in acute myeloid leukemia
(Impact Journals LLC) These Oncotarget findings demonstrate that Tomivosertib exhibits potent anti-leukemic properties on AML cells and support the development of clinical translational efforts involving the use of this drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Unraveling the mechanisms that create the individualized metabolism in leukemia
(Kumamoto University) Lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells. Cancer cells have a unique ability to metabolize substances differently from normal cells, and this ability is considered to be a promising therapeutic target. New findings may contribute to the safe and effective use of LSD1 inhibitors as potential anticancer agents, and to the development of highly specific treatments for various leukemia types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2021 Category: Cancer & Oncology Source Type: news

Hypomethylating Agents in Children With Relapsed/Refractory AML Hypomethylating Agents in Children With Relapsed/Refractory AML
Hypomethylating agents can serve as a bridge to transplant for children and young adults with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 25, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Reduced-Intensity Transplant Benefits Older Patients With AML Reduced-Intensity Transplant Benefits Older Patients With AML
Results from two large trials show that for older patients with acute myeloid leukemia (AML), survival is improved if they receive reduced-intensity conditioning before transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Media News - June 11, 2021 Category: Pharmaceuticals Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Investor Update - June 11, 2021 Category: Pharmaceuticals Source Type: news

1980 to 2017 Saw Improved Survival for Acute Myeloid Leukemia
THURSDAY, June 10, 2021 -- From 1980 to 2017, there was improvement in survival for acute myeloid leukemia (AML) in all age groups, except for those aged≥70 years, according to a study published in the June 15 issue of Cancer. Koji Sasaki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news

When cancer cells " put all their eggs in one basket "
(Cold Spring Harbor Laboratory) Normal cells usually have multiple solutions for fixing problems that may arise. But cancer cells may " put all their eggs in one basket, " getting rid of all backup plans and depending on just one solution. CSHL Professor Christopher Vakoc's lab discovered that a particular type of blood cancer, acute myeloid leukemia, came to depend on a single DNA repair method. They developed a drug that shut down the remaining pathway in lab-grown cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Media News)
Source: Roche Media News - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - May 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

From mice to men: Study reveals potential new target for treating acute myeloid leukemia
(AlphaMed Press) A study released in STEM CELLS indicates that blocking transforming growth factor beta 1 (TGFβ1) could improve hematopoiesis in patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news

UAMS Researcher Gets $1.27M for Cancer Study
A researcher with the Winthrop P. Rockefeller Cancer Institute gets a five-year, $1.27 million grant to work toward developing two treatment options for acute myeloid leukemia patients. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - May 11, 2021 Category: American Health Source Type: news

Study finds potential therapeutic target for pediatric acute myeloid leukemia
(Nemours) Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children's Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

New genetic target for blood cancer treatment
(Wellcome Trust Sanger Institute) Researchers have identified a vulnerability in some cases of acute myeloid leukaemia that could be harnessed for targeted treatment of these poor-prognosis cancers (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

Scientists develop new class of cancer drug with potential to treat leukaemia
(University of Cambridge) Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news

EU Panel Likes Azacitidine for AML Maintenance EU Panel Likes Azacitidine for AML Maintenance
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion of the drug for use as maintenance therapy in patients with acute myeloid leukemia.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

Children With Down Syndrome at Higher Risk for Leukemia
Risk particularly high for acute myeloid leukemia before age 5 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Pathology, Pediatrics, Radiology, Journal, Source Type: news

Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
LEXINGTON, Mass., April 19, 2021 -- (Healthcare Sales & Marketing Network) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food ... Biopharmaceuticals, Oncology, FDA Curis, acute myeloid leukemia, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2021 Category: Pharmaceuticals Source Type: news

Scientists identify potential drug candidates for deadly pediatric leukemia
(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates--JAK inhibitors and Mepron--hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Crnic Institute discovery may explain high risk of leukemia in children with Down syndrome
(University of Colorado Anschutz Medical Campus) Children with Down syndrome are 20-times more likely to develop acute lymphocytic leukemia (ALL) and 150-times more likely to develop acute myeloid leukemia (AML) compared to their typical peers. According to a new study by researchers at the Linda Crnic Institute for Down Syndrome, the reason could be that children with Down syndrome are more likely to present with clonal hematopoiesis (CH), a process in which a blood stem cell acquires a genetic mutation that promotes replication. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
DUBLIN, March 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and cytarabine) to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2021 Category: Drugs & Pharmacology Source Type: news

Virginia Commonwealth University Scientists Combine dPCR and High-Speed Microscopic Imaging to Reduce Cost of Diagnosing Cancers
VCU scientists used the technique to measure mutations associated with acute myeloid leukemia, potentially offering an attractive alternative to DNA sequencing More accurate but less-costly cancer diagnostics are the Holy Grail of cancer research. Now, research scientists at Virginia Commonwealth University (VCU) say they have developed a clinical laboratory diagnostic technique that could be far […] The post Virginia Commonwealth University Scientists Combine dPCR and High-Speed Microscopic Imaging to Reduce Cost of Diagnosing Cancers appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - March 24, 2021 Category: Laboratory Medicine Authors: Jude Tags: Digital Pathology Instruments & Equipment Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory Operations Laboratory Pathology Laboratory Testing Management & Operations ACS Alden Chesney MD ame Source Type: news

Drug Trial Snapshot: DAURISMO
DAURISMO is used to treat adults with newly-diagnosed acute myeloid leukemia (AML). It is to be used in patients who•are 75 years of age or older, or•have other medical conditions that prevent the use of standard chemotherapy. AML is a rapidly progressing cancer that forms in the bone marrow and (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 18, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Whole-Genome Sequencing Is Accurate for Myeloid Cancers
WEDNESDAY, March 10, 2021 -- A streamlined whole-genome sequencing approach can provide rapid and accurate genomic profiling for acute myeloid leukemia (AML) or myelodysplastic syndromes, according to a study published in the March 11 issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2021 Category: Pharmaceuticals Source Type: news

New classification of leukemia subtypes reveals potential of existing drugs
(University Health Network) Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) - called NPM1 - that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 16, 2021 Category: International Medicine & Public Health Source Type: news

Researchers take early step toward leukemia drug therapy
(McMaster University) The team has discovered that for acute myeloid leukemia (AML) patients, there is a dopamine receptor pathway that becomes abnormally activated in the cancer stem cells. This inspired the clinical investigation of a dopamine receptor-inhibiting drug thioridazine as a new therapy for patients, and their focus on adult AML has revealed encouraging results. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Sinai team builds first model acute myeloid leukemia progression using CRISPR
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2021 Category: Cancer & Oncology Source Type: news

New maintenance treatment for acute myeloid leukemia prolongs the lives of patients
(Weill Cornell Medicine) Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2021 Category: Cancer & Oncology Source Type: news

New drug combination shows promise as powerful treatment for AML
(Sanford Burnham Prebys Medical Discovery Institute) Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news

Leukemia: New Adverse Event With PARP Inhibitors in Cancer Leukemia: New Adverse Event With PARP Inhibitors in Cancer
Late toxicities in the form of myelodysplastic syndrome and acute myeloid leukemia can occur even a brief exposure to PARP inhibitors, and both are associated with a high mortality rate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Key Presentations on Acute Myeloid Leukemia From ASH 2020 Key Presentations on Acute Myeloid Leukemia From ASH 2020
Highlights in acute myeloid leukemia from ASH 2020 include study results for combination therapy in newly diagnosed AML patients with FLT-3, and CPX-351 vs 7 + 3 in older adults with secondary or high-risk-prognosis AML.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Oral Azacitidine Benefits Some Older Adults With AML
TUESDAY, Dec. 29, 2020 -- For older patients with acute myeloid leukemia (AML) who are in remission after chemotherapy, those receiving maintenance therapy with the oral formulation of azacitidine (CC-486) versus placebo had longer overall and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2020 Category: Pharmaceuticals Source Type: news

Drug offers hope for acute myeloid leukemia treatment in older adults
A new drug treatment for acute myeloid leukemia improves overall survival in those with the deadly blood cancer by up to 10 months, according to a clinical trial published by the New England Journal of Medicine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 24, 2020 Category: Consumer Health News Source Type: news

Global trial reveals life saving drug for acute myeloid leukemia
(Monash University) Results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML), significantly improving survival in older patients, over the age of 55, with the disease. AML is the most acute blood cancer in adults and its incidence increases with age, with a poor prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 23, 2020 Category: Cancer & Oncology Source Type: news

Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
TOKYO, Dec. 21, 2020 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that a Phase 3 trial of XOSPATA® (gilteritinib) plus azacitidine versus ... Biopharmaceuticals, Oncology Astellas Pharma, XOSPATA, gilteritinib, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 21, 2020 Category: Pharmaceuticals Source Type: news

Novel combination therapy may help overcome mTOR drug resistance in AML
(Cincinnati Children's Hospital Medical Center) Despite high hopes, mTOR inhibitors have not shown much success against acute myeloid leukemia. But a study in PNAS led by experts at Cincinnati Children's suggests a combination therapy may prove more effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Integrated Palliative and Oncology Care Improves QOL in Leukemia
FRIDAY, Dec. 18, 2020 -- For patients with acute myeloid leukemia (AML) receiving intensive chemotherapy, there are substantial improvements in quality of life (QOL) and psychological distress with integrated palliative and oncology care (IPC),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

Palliative care improves quality of life for patients with advanced blood cancer
(Massachusetts General Hospital) A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Why Do Black Patients Fare Worse With Blood Cancer Than Whites?
FRIDAY, Dec. 11, 2020 -- A pair of studies shed new light on why a relatively rare blood cancer— acute myeloid leukemia (AML)— is more deadly among Black patients. The takeaways: Where patients live and their access to quality health... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 11, 2020 Category: General Medicine Source Type: news

ASH: Black Race Linked to Poorer Survival in AML
TUESDAY, Dec. 8, 2020 -- Self-reported patient race is the most important factor associated with poorer survival in patients with acute myeloid leukemia (AML), according to a study presented at the annual meeting of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news